S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Modern Day Options Trading For Beginners! (Ad)pixel
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Modern Day Options Trading For Beginners! (Ad)pixel
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Modern Day Options Trading For Beginners! (Ad)pixel
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
NYSE:CRL

Charles River Laboratories International - CRL Competitors

$191.89
-5.57 (-2.82%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$190.96
$196.00
50-Day Range
$191.89
$259.92
52-Week Range
$181.36
$308.15
Volume
598,342 shs
Average Volume
582,382 shs
Market Capitalization
$9.78 billion
P/E Ratio
20.26
Dividend Yield
N/A
Price Target
$270.83

CRL vs. MEDP, INCY, SYNH, ICLR, UTHR, HSIC, TEVA, RGEN, PEN, and QGEN

Should you be buying Charles River Laboratories International stock or one of its competitors? The main competitors of Charles River Laboratories International include Medpace (MEDP), Incyte (INCY), Syneos Health (SYNH), ICON Public (ICLR), United Therapeutics (UTHR), Henry Schein (HSIC), Teva Pharmaceutical Industries (TEVA), Repligen (RGEN), Penumbra (PEN), and Qiagen (QGEN). These companies are all part of the "medical" sector.

Charles River Laboratories International vs.

Medpace (NASDAQ:MEDP) and Charles River Laboratories International (NYSE:CRL) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, community ranking, dividends, profitability, valuation, media sentiment and analyst recommendations.

Charles River Laboratories International has higher revenue and earnings than Medpace. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medpace$1.46 billion3.86$245.37 million$7.3224.80
Charles River Laboratories International$3.98 billion2.46$486.23 million$9.4720.26

Medpace has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.

In the previous week, Medpace had 2 more articles in the media than Charles River Laboratories International. MarketBeat recorded 10 mentions for Medpace and 8 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.70 beat Medpace's score of 0.39 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medpace
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Charles River Laboratories International
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

82.5% of Medpace shares are owned by institutional investors. Comparatively, 97.8% of Charles River Laboratories International shares are owned by institutional investors. 20.6% of Medpace shares are owned by insiders. Comparatively, 1.1% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Medpace presently has a consensus target price of $235.50, indicating a potential upside of 29.74%. Charles River Laboratories International has a consensus target price of $267.75, indicating a potential upside of 39.53%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts plainly believe Charles River Laboratories International is more favorable than Medpace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medpace
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Charles River Laboratories International
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.82

Medpace has a net margin of 16.81% compared to Charles River Laboratories International's net margin of 12.23%. Medpace's return on equity of 60.42% beat Charles River Laboratories International's return on equity.

Company Net Margins Return on Equity Return on Assets
Medpace 16.81% 60.42% 18.38%
Charles River Laboratories International 12.23% 20.98% 7.71%

Charles River Laboratories International received 148 more outperform votes than Medpace when rated by MarketBeat users. However, 64.39% of users gave Medpace an outperform vote while only 63.16% of users gave Charles River Laboratories International an outperform vote.

CompanyUnderperformOutperform
MedpaceOutperform Votes
320
64.39%
Underperform Votes
177
35.61%
Charles River Laboratories InternationalOutperform Votes
468
63.16%
Underperform Votes
273
36.84%

Summary

Medpace and Charles River Laboratories International tied by winning 9 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRL vs. The Competition

MetricCharles River Laboratories InternationalCommercial physical research IndustryMedical SectorNYSE Exchange
Market Cap$9.78B$3.79B$4.37B$14.13B
Dividend YieldN/A1.15%2.41%3.93%
P/E Ratio20.2612.72131.7721.42
Price / Sales2.4610,157.223,490.0549.33
Price / Cash11.3016.0719.6416.31
Price / Book3.2825.814.516.77
Net Income$486.23M$84.68M$115.19M$868.69M
7 Day Performance-2.24%0.44%0.42%1.35%
1 Month Performance-12.51%-13.29%-7.23%-6.31%
1 Year Performance-34.05%-39.69%-16.00%-15.29%

Charles River Laboratories International Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MEDP
Medpace
2.9853 of 5 stars
$178.78
-3.1%
$235.50
+31.7%
+13.6%$5.55B$1.46B24.425,200Short Interest ↑
INCY
Incyte
3.1049 of 5 stars
$72.26
-1.7%
$87.54
+21.1%
-10.9%$16.11B$3.39B47.542,324
SYNH
Syneos Health
2.9775 of 5 stars
$33.84
-3.4%
$54.00
+59.6%
-56.9%$3.49B$5.39B13.1729,395Short Interest ↓
Positive News
ICLR
ICON Public
2.7991 of 5 stars
$208.63
-2.2%
$266.70
+27.8%
-12.9%$17.05B$7.74B34.0341,100
UTHR
United Therapeutics
2.9883 of 5 stars
$212.99
-4.2%
$291.55
+36.9%
+24.9%$9.86B$1.94B14.18965Insider Selling
Analyst Revision
HSIC
Henry Schein
2.4526 of 5 stars
$78.45
-2.2%
$85.89
+9.5%
-10.0%$10.30B$12.65B20.1722,000Short Interest ↓
TEVA
Teva Pharmaceutical Industries
1.7486 of 5 stars
$8.73
-0.8%
$10.78
+23.5%
+2.3%$9.70B$14.93B-4.1236,826Short Interest ↓
RGEN
Repligen
2.5322 of 5 stars
$166.25
-4.5%
$216.86
+30.4%
-6.7%$9.67B$801.54M51.152,025Analyst Report
News Coverage
PEN
Penumbra
2.0462 of 5 stars
$273.61
+1.3%
$265.42
-3.0%
+34.9%$10.45B$847.13M-4,560.173,900
QGEN
Qiagen
1.9932 of 5 stars
$45.94
-1.0%
$55.53
+20.9%
-5.7%$10.46B$2.14B24.976,000Short Interest ↓
This page (NYSE:CRL) was last updated on 3/29/2023 by MarketBeat.com Staff